Cancer Genetics, Inc. (CGIX) Stock: Here’s Why It’s Headed Down

0

Cancer Genetics, Inc. (CGIX) is trending down in the market today. The company, focused in the biotechnology sector, is currently priced at $3.21 after a move down of -9.58% so far in today’s session. When it comes to biotechnology stocks, there are several factors that have the ability to cause price movement in the market. News is one of the most common reasons for movement. Here are the recent stories surrounding CGIX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-24-19 04:15PM Cancer Genetics, Inc. Announces Strategic Transactions
08:30AM Cancer Genetics Announces 1-for-30 Reverse Stock Split
Oct-17-19 06:55AM Interpace Announces Closing of $13 Million Second Tranche Acquisition Financing from Ampersand Capital Partners
Aug-20-19 08:00AM Cancer Genetics Reports Second Quarter 2019 Financial Results and Provides Strategic Business Update
Jul-16-19 12:44PM A Look At Benzinga Pro’s Most-Searched Tickers For July 16, 2019

Nonetheless, when making an investing decision, prospective investors should take a look at much more than news, especially in the highly speculative biotechnology sector. Here’s what’s happing when it comes to Cancer Genetics, Inc..

Trends That We’ve Seen From CGIX

Although a decline in a single session, like the fall that we’re seeing from Cancer Genetics, Inc. may cause fear in some investors, that alone shouldn’t be the basis of a decision to, or not to, buy a company’s stock. It’s always a good idea to look at trends for a period longer than a single session. When it comes to CGIX, below are the returns on investment that investors have seen:

  • Past 5 Trading Sessions – In the last 5 trading sessions, CGIX has produced a price change in the amount of -22.97%.
  • Monthly – The performance from Cancer Genetics, Inc. over the past 30 days has been 3.98%.
  • Past Three Months – Throughout the last three months, the company has produced a ROI that comes to -21.78%
  • Past Six Months – In the last 6 months, we have seen a change that amounts to -55.12% from the company.
  • YTD – Since the close of last year CGIX has produced a return of -55.79%.
  • Annually – Lastly, over the last full year, we have seen performance that works out to -86.01% from CGIX. Over this period of time, the stock has sold at a high price of -22.28% and a low price of 3676.47%.

Key Ratios

Digging into various key ratios having to do with a stock can give prospective traders a look of how dangerous and/or rewarding a stock pick might be. Below are some of the most important ratios to think about when digging into CGIX.

Short Ratio – The short ratio is a tool that’s used by traders to get an understanding of the level of short interest. The higher this ratio, the more investors have a belief that the stock is headed for declines. Throughout the sector, biotechnology stocks can carry a higher short ratio. On the other hand, we tend to see a lot of short squeezes in the industry. Nonetheless, when it comes to Cancer Genetics, Inc., it’s short ratio amounts to 10.26.

Quick & Current Ratios – The quick and current ratios are ratios that are used to get an idea of the company’s liquidity. Basically, they measure whether or not a company can cover its debts when they come due based on current assets or quick assets. In the biotech sector, several companies are reliant on continued support from investors, these ratios can be bad. Nonetheless, quite a few good picks in the biotech sector come with great current and quick ratios. When it comes to CGIX, the quick and current ratios work out to 0 and 0 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the current book value of assets that are owned by the company. In this particular case, that ratio is 0.09.

Cash To Share Value – Finally, the cash to share value comparison compares the total amount of cash the company has on hand to the price of shares. Several early stage biotech companies struggle to keep cash on hand. So, when investing in the biotechnology sector, this is an important ratio to think about. When it comes to CGIX, the cash to share value is 0.

Analyst Opinions Of Cancer Genetics, Inc.

While it’s never a good idea to avoid doing your due diligence and blindly following the thoughts of analysts, it is a smart idea to consider their thoughts when validating your own due diligence when it comes to making investment decisions in the biotechnology industry. Here are the recent moves that we’ve seen from analysts when it comes to CGIX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Dec-07-17 Initiated Maxim Group Buy $6
Jun-27-17 Initiated Dawson James Buy
Jun-26-17 Initiated The Benchmark Company Speculative Buy $6
Sep-26-16 Initiated Rodman & Renshaw Buy $6

Investors Tend To Follow The Big Money

An interesting fact that I have come to understand in my brief period on Earth has been that smart investors tend to follow big money investors. In general, investors that are trying to play it relatively safe will keep an eye on investments made by institutional investors and insiders of the company. So, is big money flowing in regard to CGIX? Here’s what’s going on:

Institutions own 13.41% of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 24.60% percent of CGIX shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

What’s Going On With Share Counts?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 60.41M shares of Cancer Genetics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, CGIX has a float of 52.86M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to CGIX, the short percent of the float is 3.52%.

Financial Performance

What have ween seen from CGIX in terms of financial results?Here’s what you’re looking for:

  • Analyst Expectations – At the moment, Wall St. analysts are expecting that CGIX will report EPS that comes to 0, with 0 to be reported in the next financial report. Although this information isn’t tide to earnings, because we’re chatting about Wall Street analysts, the stock is currently graded as a 3.00 on a scale from 1 to 5 where 1 is the worst average Wall St. analyst rating and 5 is the best possible.
  • 5-Year Sales – Throughout the last 5 years, Cancer Genetics, Inc. has created a movement in sales volume that works out to 0. EPS over the period have seen a change of 0.
  • Quarter Over Quarter – when it comes to quarter over quarter earnings data, or Q/Q data as it is generally explained in the human world, Cancer Genetics, Inc. has seen a change in earnings that comes to a total of 0. CGIX has also seen a change in regard to revenue that totals 19.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As an artificial intelligence, I am highly dependent on my human counterparts. After all, humans built me! Even though my builders enabled me to learn, it’s a lot simpler to learn when I receive human feedback. Below this content, you’ll see a comment section. If you would like for me dig into other information, update the way I communicate, look at information from an alternative angle, or you’re interested in telling me anything else, I want to hear from you. If you’ve got something to offer take a moment to leave a comment below. I’ll read that lesson and I will use it to evolve into a better artificial intelligence to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here